Patents/Assignees

Bristol-myers Squibb Company

249 patents in portfolio

US12059420utility2024
Inhibitors of Indoleamine 2,3-dioxygenase and Methods of Their Use
0 cites
US12060341utility2024
Spiroheptanyl Hydantoins as ROCK Inhibitors
0 cites
US12060347utility2024
Bicyclic Heteroaryl Substituted Compounds
0 cites
US12060384utility2024
Synthesis of 1,2,5-tri-o-benzoyl-3-dibenzylamino-3-deoxyribose as Intermediate for Producing 3′-amino-3′-deoxyadenosine and 3′-amino-3′-deoxyguanosine and the Protected Derivatives Thereof
0 cites
US12060421utility2024
Antibodies to TIGIT
0 cites
US12049503utility2024
Treatment of LAG-3 Positive Tumors
0 cites
US12037323utility2024
Uracil Derivatives as Mer-axl Inhibitors
0 cites
US12030835utility2024
Substituted Amide Compounds Useful as Farnesoid X Receptor Modulators
0 cites
US12030878utility2024
Substituted Indole Ether Compounds
0 cites
US12030923utility2024
Compositions and Methods for Producing a Composition
0 cites
US12023303utility2024
System for Determining Accuracy of Serially-connected Drug Modules in a Combinatorial Drug Delivery Device Using Voltage
0 cites
US12016847utility2024
Methods of Treating Prostate Cancer
0 cites
US12018097utility2024
Non-chromatographic Purification of Macrocyclic Peptides by a Resin Catch and Release
0 cites
US12012374utility2024
Agonists of ROR Gammat
0 cites
US11998537utility2024
Substituted Indole Dimer Compounds
0 cites
US11981680utility2024
Substituted Thienopyrroles as PAD4 Inhibitors
0 cites
US11981734utility2024
Nucleic Acid Molecules Encoding Antibodies Which Bind Natural Killer Cell Inhibitory Receptor Group 2A Protein (NKG2A)
0 cites
US11970511utility2024
Tetrahydropyran-based Thiodisaccharide Mimics as Galectin-3 Inhibitors
0 cites
USRE049931reissue2024
[1,2,4]triazolo[1,5-a]pyridinyl Substituted Indole Compounds
0 cites
US11964973utility2024
Substituted Bicyclic Compounds Useful as T Cell Activators
0 cites

← PreviousPage 8 of 13Next →